Illumina, Inc. (ILMN)
Truveta sells stakes to Regeneron, Illumina in deal to build genetic database
Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals , Illumina and 17 U.S. health systems will take a $320 million stake in the company as part of a deal to build the world's largest genetic database.
ILMN Stock Set to Gain From Latest Updates to the NovaSeq X Series
Illumina advances NovaSeq X Series with a software upgrade and the new 25B 100-cycle and 200-cycle kits.
Grail: What Lies Ahead After the Illumina Spin-Off
This spotlight on the ROBO Global Healthcare Technology and Innovation Index highlights Grail (GRAL), a standout within the Genomics subsector. It is a key component of the $53.6 million ROBO Global Healthcare Technology and Innovation ETF (HTEC).
Illumina, Inc. (ILMN) CFO Ankur Dhingra Hosts Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)
Illumina, Inc. (NASDAQ:ILMN ) Annual Evercore ISI HealthCONx Healthcare Conference December 3, 2024 9:00 AM ET Company Participants Ankur Dhingra - CFO Sallilyn Schwartz - VP of Investor Relations Conference Call Participants Vijay Kumar - Evercore ISI Vijay Kumar Great. Thanks, everyone, for joining us this afternoon.
Illumina, Inc. (ILMN) CFO Ankur Dhingra Hosts Wolfe Research 2024 Healthcare Conference (Transcript)
Illumina, Inc. (NASDAQ:ILMN ) Wolfe Research 2024 Healthcare Conference Call November 20, 2024 9:20 AM ET Company Participants Ankur Dhingra - Chief Financial Officer Conference Call Participants Doug Schenkel - Wolfe Research Doug Schenkel All right. Good morning, everybody.
ILMN Stock Set to Gain From Expansion of TruSight Oncology Portfolio
Illumina's new TSO 500 v2 assay aims to enable CGP of tumors, bolstering its TruSight Oncology portfolio.
Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Interpreting Illumina (ILMN) International Revenue Trends
Explore how Illumina's (ILMN) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Illumina: Q3 Confirms Improving Fundamentals
Illumina is the leader in the undisputed Next Generation Sequencing market. Grail divestment is behind, enabling a margin expansion and fueling a more robust cash flow generation. The stock was down after hours, as much good news has been priced in the recent rally.
ILMN Q3 Earnings Top, '24 Sales View Down, Stock Dips in Aftermarket
Illumina's third- quarter revenues from the consumables business show robust growth, offset by the declining instruments business.
Illumina (ILMN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Illumina, Inc. (ILMN) Q3 2024 Earnings Call Transcript
Illumina, Inc. (NASDAQ:ILMN ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Corporate Participants Salli Schwartz - Vice President of Investor Relations Jacob Thaysen - Chief Executive Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Doug Schenkel - Wolfe Research Puneet Souda - Leerink Partners Vijay Kumar - Evercore ISI Dan Brennan - TD Cowen Tycho Peterson - Jefferies David Westenberg - Piper Sandler Conor McNamara - RBC Capital Markets Dan Arias - Stifel Patrick Donnelly - Citi Subha Nambi - Guggenheim Sung Ji Nam - Scotiabank Ben Mee - Stephens Dan Leonard - UBS Operator Good day, ladies and gentlemen, and welcome to the Third Quarter 2024 Illumina Earnings Conference Call. At this time, all participants are in a listen-only mode.
